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Abstract
Background: DNA methylation and histone acetylation are epigenetic modifications that act as regulators of gene 
expression. Aberrant epigenetic gene silencing in tumours is a frequent event, yet the factors which dictate which 
genes are targeted for inactivation are unknown. DNA methylation and histone acetylation can be modified with the 
chemical agents 5-aza-2'-deoxycytidine (5-aza-dC) and Trichostatin A (TSA) respectively. The aim of this study was to 
analyse de-methylation and re-methylation and its affect on gene expression in colorectal cancer cell lines treated with 
5-aza-dC alone and in combination with TSA. We also sought to identify methylation patterns associated with long 
term reactivation of previously silenced genes.
Method: Colorectal cancer cell lines were treated with 5-aza-dC, with and without TSA, to analyse global methylation 
decreases by High Performance Liquid Chromatography (HPLC). Re-methylation was observed with removal of drug 
treatments. Expression arrays identified silenced genes with differing patterns of expression after treatment, such as 
short term reactivation or long term reactivation. Sodium bisulfite sequencing was performed on the CpG island 
associated with these genes and expression was verified with real time PCR.
Results: Treatment with 5-aza-dC was found to affect genomic methylation and to a lesser extent gene specific 
methylation. Reactivated genes which remained expressed 10 days post 5-aza-dC treatment featured hypomethylated 
CpG sites adjacent to the transcription start site (TSS). In contrast, genes with uniformly hypermethylated CpG islands 
were only temporarily reactivated.
Conclusion: These results imply that 5-aza-dC induces strong de-methylation of the genome and initiates reactivation 
of transcriptionally inactive genes, but this does not require gene associated CpG island de-methylation to occur. In 
addition, for three of our selected genes, hypomethylation at the TSS of an epigenetically silenced gene is associated 
with the long term reversion of gene expression level brought about by alterations in the epigenetic status following 5-
aza-dC treatment.
Background
DNA methylation is an epigenetic modification that
occurs on cytosine residues in the sequence context 5'-
CG-3'. It is well established that DNA methylation acts as
a transcriptional repressor of gene expression via recruit-
ment of repressive proteins. These include the Methyl-
CpG Binding Protein 1 (MeCP1) and proteins with a
methyl-binding domain, such as MBD1, MBD2, MBD3,
MBD4 and MeCP2. These proteins hinder transcription
through the recruitment of other factors such as
nucleosome remodelling complex [1]. In the case of
MeCP2, the protein is capable of binding to a single sym-
metrically methylated cytosine and contributing to the
long-term repression of transcription [2]. The binding of
these additional protein factors leads to condensation of
DNA and confers stability to the chromosome.
In normal cells, repetitive elements such as long inter-
spersed nucleotide elements, Alu repeats, transposable
elements, and satellite and non-satellite sequences which
together make up almost half of the genome, are methy-
lated [3-5]. Methylation of these regions largely contrib-
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utes to the level of global methylation, and it is likely that
these regions are most drastically affected by aberrant
hypomethylation and the stability that the methylation
once conferred to the chromosomes is lost. Aberrant
methylation is one of the more frequent molecular
changes observed in tumour cells [6] and typically
involves the reversal of normal methylation patterns. It
has been known for some time that common changes
involve genome wide hypomethylation, which impinges
on the expression of oncogenes [7], loss of imprinting and
hypermethylation of tumour suppressor genes [8]. These
are believed to be a cause rather than a consequence of
the malignant process as they arise early in disease devel-
opment [9]. Supporting this is strong evidence that global
hypomethylation plays a crucial role in causing genomic
instability in colorectal carcinogenesis [10]. Alternatively,
gene specific hypermethylation is another mechanism
which can initiate carcinogenesis. This mechanism of
gene silencing has been shown by the correlation of
methylated promoters with a subsequent decrease in cor-
responding gene expression. The precise set of events
that govern which CpG residues are methylated are not
understood, nor is the mechanism that causes hypometh-
ylation [11].
5-aza-2'-deoxycytidine (5-aza-dC) is a strong inducer
of DNA de-methylation. It is an analogue of cytosine, that
when incorporated into DNA, irreversibly binds the
methyltransferase enzymes as they attempt to methylate
the cytosine analogue. This depletion of methyltrans-
ferase in the cell results in passive de-methylation, which
is known to reactivate epigenetically silenced genes [12].
5-aza-dC has demonstrated its most positive effect in the
treatment of hematologic malignancy such as myelodys-
plastic syndromes [13]. In this scenario, its effectiveness
may be due to sensitisation to other reagents or the re-
activation of silenced genes which have an apoptotic
effect. Another agent which affects the epigenetic status
of genes is Trichostatin A (TSA). TSA was originally
developed as an antifungal agent [14], but was also found
to lead to the accumulation of acetylated histones via the
inhibition of Histone Deacetylase [15]. The presence of
an acetyl group on a lysine amino acid in the N-terminal
end of core histone proteins neutralises the positive
charge carried by the lysine, weakening the association
between the nucleosome and DNA [16] to favour tran-
scriptional activity. Reports have demonstrated a syner-
gistic effect of TSA with 5-aza-dC in the re-expression of
epigenetically silenced genes [17-20]. Currently it is not
known how methylation patterns are altered with 5-aza-
dC, and how or if these patterns can be restored when
drug treatment ceases.
The aim of this study was to examine patterns of DNA
methylation in several colorectal cancer (CRC) cell lines,
to assess how these patterns are affected by drugs which
alter epigenetic status, and profile the re-methylation
process at both a genome-wide and gene specific level.
Currently, the process of re-methylation following 5-aza-
dC is not well documented.
Methods
Cell Culture
Colorectal cancer cells HCT116, SW48, SW480, HT29
and a fibroblast cell line derived from a healthy donor
were all cultured in DMEM supplemented with 10% Foe-
tal Calf Serum (Sigma-Aldrich, St Louis, MO) at 37°C and
5% CO2. De-methylation was induced with 5-aza-dC
(Sigma-Aldrich) treatment at a pre-determined concen-
tration that induced maximal de-methylation of the DNA
without killing the cells. Culture media for LoVo and the
fibroblast cells contained 10 μM 5-aza-dC, whilst all
other cells were treated with 15 μM. Cells were incubated
for 72 h with 5-aza-dC with the culture media being
replaced every 24 h with fresh media containing 5-aza-
dC. DNA and RNA were extracted before drug treatment
and after 72 h of drug treatment. Immediately following
drug treatment (72 h), a fraction of the cells were washed
twice with PBS and allowed to continue growing under
regular drug-free conditions. At every two days following
cessation of treatment, DNA and RNA were extracted
while a fraction of the cells continued to be incubated
until ten days of drug free growth. The experiment was
also performed on HCT116 cells continuously exposed to
150 ηM Trichostatin A (Sigma-Aldrich) during the treat-
ment and re-methylation period to assess the affect of
histone acetylation on DNA re-methylation. This concen-
tration chosen has previously been shown to cause hyper-
acetylation in the HCT116 cell line [21].
Cytotoxicity and Apoptosis testing
The assessment of cytotoxicity and apoptosis was under-
taken using pooled cell cultures as per the assay protocol
provided with the detection kits. For practicality, the
HCT116, SW480 and LoVo cell lines were assayed. Cyto-
toxicty was quantified using Cytotoxicty Detection Kit
(Roche Diagnostics, Mannheim, Germany) according to
manufacturer's instructions. Apoptosis was determined
using an Annexin V Apoptosis Detection Kit from BD
Biosciences and analysed on a BD FACSCantoII flow
cytometer (Becton Dickinson, Franklin Lakes, NJ) follow-
ing the manufacturer's instructions.
High Performance Liquid Chromatography (HPLC) Analysis 
of Global Methylation Levels
50 μg of DNA was treated with 5 μL RNAse Cocktail
(Ambion, Austin, TX) to remove any residual RNA which
would interfere with HPLC analysis. DNA was then phe-
nol-chloroform extracted and resuspended in sterile
water. DNA aliquots of 3 μg were digested with 1.5 U ofMossman et al. BMC Cancer 2010, 10:366
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Nuclease P1 (US Biological, Swampscott, MA) and incu-
bated at 37°C for 16 h. Following digestion, 2 μL of Calf
Intestinal Alkaline Phosphatase (Promega, Madison, WI)
was added and incubated at 37°C for a further two hours.
Separation of nucleosides was performed on a Varian Star
Chromatography workstation with a Supelcosil LC-18-
DB column (Sigma-Aldrich) over 30 min at 35°C with
absorbance monitored at 278 nm. Peak areas were quan-
t i f i e d  w i t h  S t a r  R e v i e w e r  S o f t w a r e  ( V a r i a n ,  P a l o  A l t o ,
CA) and the 5-methylcytosine content was expressed as a
percentage of the total cytosine pool after correction for
extinction co-efficients. Standard deviations were calcu-
lated and a T-test was employed to compare expression
levels in drug treated cells against untreated cells. P-val-
ues less than 0.05 were considered to be statistically sig-
nificant.
Illumina arrays and Analysis
Illumina Human Ref-8 expression arrays (Illumina, Hay-
w a r d ,  C A )  w e r e  u s e d  t o  m e a s u r e  g e n o m e  w i d e  g e n e
expression at four chosen time points; untreated cells,
treated cells (day 0 of re-methylation), and at four (d4)
and ten days (d10) of drug free growth and re-methyla-
t i o n .  T h e s e  t i m e  po i n t s  w e r e  s e l e c t e d  b a s ed  o n  g l o b a l
methylation levels at these time points. Untreated and
treated cells were used to identify changes caused by 5-
aza-dC, whilst day 4 would allow an intermediate and day
10 a final assessment of the changes in gene expression
during re-methylation. Data analysis was performed in
Genespring 7.3.1. software (Agilent, Foster City, CA).
Genes were classified according to their expression pat-
tern, and were selected with the aim of comparing methy-
lation patterns in genes temporarily reactivated and those
still expressed after 10 days of drug free growth. The
genes selected for analysis were CDO1, HSPC105,
MAGEA3, RNF113B., ZFP3 and two colorectal cancer
related genes CDKN2A  and  MLH1. These genes dis-
played different expression patterns in the HT29, SW480,
SW48 and HCT116 cell lines that could be further exam-
ined.
Bisulfite conversion, PCR and direct sequencing
DNA was converted in duplicate using a Qiagen Epitect
Bisulfite conversion kit (Qiagen, Valencia, CA) using 2 μg
of phenol-chloroform purified DNA. Samples were
eluted in 30 μL of elution buffer and an aliquot was
diluted 1:3 prior to PCR and stored at 4°C, whilst the
remaining fraction was stored at -20°C. CpG islands sur-
rounding the transcription start site of genes were tar-
geted in PCR analysis using the primers listed in
Additional File 1: Table S1. Primers included a non-CpG
cytosine at the 3' end in order to preferentially amplify
converted DNA sequences. Amplified products were
purified with Ampure magnetic bead clean-up system
(Agencourt, Beverly, MA). Big Dye Terminator Version
3.1 sequencing mastermix was used with the forward
PCR primer and reactions were purified with CleanSEQ
magnetic clean-up system (Agencourt). Sequencing was
performed in duplicate on an ABI 3730 sequencer and
data analysis was carried out using Sequence Scanner
software (Applied Biosystems, Foster City, CA). The per-
centage methylation at each CpG was determined by
dividing the cytosine peak by the combined heights of the
cytosine and thymine peaks as described previously [22].
mRNA expression analysis
Extracted RNA was converted to cDNA using Super-
script II (Invitrogen, Carlsbad, CA). Real time PCR was
performed using an ABI 7500 real time PCR machine and
SYBR green mastermix (Applied Biosystems) and prim-
ers listed in Additional File 1: T able T1. Reactions were
carried out in triplicate and the fold change in expression
was normalised to the β-actin housekeeping gene using
the 2-ΔΔCt method. For the purpose of calculating fold
changes in expression, genes with no detectable expres-
sion were assigned a Ct value of 40. Standard deviations
were calculated and a T-test was employed to compare
expression levels in drug treated cells against untreated
cells. P-values less than 0.05 were considered to be statis-
tically significant.
Ethical Approvals
This study was deemed exempt from ethics approval
from the University of Newcastle, and consent was not
required due to use of cell lines.
Results
Global Methylation levels
Quantitative HPLC indicated that global methylation was
lower in all CRC cell lines in comparison to the fibroblast
cell line, with a difference of at least 2% in total methy-
lated cytosine (Figure 1). Whilst all cancer cell lines dis-
played hypomethylation, there were differences in global
Figure 1 Global re-methylation in cell lines. All cells exhibited dem-
ethylation after 5-aza-dC treatment, and re-methylation occurred over 
the 10 days of drug free growth.Mossman et al. BMC Cancer 2010, 10:366
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methylation levels indicating these cells exhibit unique
methylation profiles. The cancer cell line HT29 displayed
the largest difference in methylation levels compared to
the control fibroblast cell line with a total methylated
cytosine content difference of 3.75%.
Global methylation response to 5-aza-dC and re-
methylation
Following treatment of cells with 5-aza-dC over 72 hours,
there was a substantial decrease of genomic DNA methy-
lation. The decrease in global methylation in the SW48,
SW480, HCT116 and LoVo cell lines was greater than
50%, whilst the decrease in fibroblast and HT29 cell lines
were not as extensive (Figure 1). Nonetheless, all treated
cells had significantly lower levels of methylation com-
pared to untreated cells (p < 0.01). By the tenth day of
drug free growth, global methylation levels approached
those observed prior to drug treatment, and the HT29
cell line had reached pre-treatment levels by Day 8. This
observation suggests there is remodelling of the chroma-
tin state. Cytotoxicity was monitored and found to be ele-
vated following drug treatment, which subsequently
receded as growth was continued in drug-free media
( A d d i t i o n a l  F i l e  2 :  F i gu r e  S 2 ) .  S i m i la r l y ,  a n  i n c r e as e  i n
apoptosis was induced by 5-aza-dC exposure, which
gradually diminished during the drug free growth period
(Table 1).
Global methylation response to combined 5-aza-dC and 
TSA and re-methylation
Combined TSA and 5-aza-dC treatment was performed
on the HCT116 cell line to observe whether histone
acetylation would influence the process of DNA re-meth-
ylation. Measurement of genomic methyl-cytosine levels
revealed no synergistic effect of combined TSA and 5-
aza-dC treatment on the de-methylation and no influence
of acetylated histones on the re-methylation process in
these cells (Table 2).
Gene-expression analysis
Numerous silenced genes were reactivated after 72 h
treatment with 5-aza-dC in each cell line as determined
b y  I l l u m i n a  e x p r e s s i o n  m i c r o a r r a y s .  I n  t h e  c a n c e r  c e l l
lines, eight genes were commonly reactivated (Table 3)
and a greater number of these remained expressed 10 d
post treatment, whilst more short term reactivation was
observed in the fibroblasts (Table 4). Hyper-acetylation
induced by TSA in HCT116 cells resulted in an increased
number of long term and fewer short term reactivated
genes compared with 5-aza-dC treatment alone. Of the
511 genes temporarily reactivated with 5-aza-dC in
HCT116 cells, 165 were re-expressed in enduring manner
when also subjected to 5-aza-dC and TSA combination
treatment, suggesting a role of histone acetylation in long
term reactivation.
Differences were observed in the resulting level of
expression of reactivated genes between cell lines in the
days following removal of 5-aza-dC. Filtering of the data
allowed categorization of two groups of reactivated
genes; those that remained highly expressed 10 d post
treatment, and those which reverted to an inactive or
lowly expressed state (Figure 2). Lists of genes which were
expressed according to these opposing groups in two dif-
ferent cells lines were generated. Genes associated with a
CpG island were randomly selected for bisulphite
sequencing analysis to allow comparisons between long
and short term reactivated genes.
Table 1: Cell Death induced by 5-aza-dC and during recovery period.
Cell Line Time Point Viable (%) Necrotic (%) Apoptotic (%)
HCT116 Untreated 94.6 5.2 0.2
5-aza-dC treated 94.0 5.5 0.5
4 d post treatment 89.8 9.9 0.3
10 d post treatment 94.0 5.6 0.4
SW480 Untreated 99.8 0.1 0.1
5-aza-dC treated 80.3 14.2 5.5
4 d post treatment 90.5 8.7 1.4
10 d post treatment 92.6 6.2 1.2
LoVo Untreated 78.4 9.4 12.2
5-aza-dC treated 67.2 7.0 25.8
4 d post treatment 67.0 10.7 22.3
10 d post treatment 77.6 11.3 11.1
Necrosis and cells undergoing apoptosis increased after 5-aza-dC exposure. The number of necrotic cells remained elevated ten days post 
treatment in SW480 and LoVo whilst apoptosis was decreasing in all cell lines ten days post treatment.Mossman et al. BMC Cancer 2010, 10:366
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Gene methylation and expression in response to 5-aza-dC
Bisulfite sequencing of seven individual gene promoter
regions revealed that de-methylation and re-methylation
changes observed at the genome-wide level were not
reflected in CpG Island (CGI) methylation levels of the
seven genes examined. Global levels decreased by over
50% in some cell lines, however the reduction of methyla-
tion at specific gene CGIs was significantly less. The
highest de-methylation observed at a specific gene was
~25% at the RNF113B CGI in the HT29 (See Additional
File 3: Figure S3), SW480 and HCT116 cell lines.
Up to 400 bp of sequence data was analysed by bisulfite
sequencing of the CGIs surrounding the Transcription
Start Site and where possible, the ATG start codon of the
respective gene. Several genes revealed the presence of
hypomethylated cytosines within an otherwise hyperm-
ethylated CGI, and frequently the hypomethylated cyto-
sines would lie in close proximity to the TSS. Genes
demonstrating this feature were the MAGEA3
(NM_005362.3) (Figure 3), CDO1  (NM_001801.2) and
HSPC105 (NM_145168.2) in SW480 cells, MAGEA3 and
CDO1 in HT29 cells (Additional File 4: Figure S4) and
MLH1 (NM_000249.2) in SW48 cells (Additional File 5:
Figure S5). These genes all appeared to be epigenetically
silenced in untreated cells and were reactivated and
highly expressed 10 days after 5-aza-dC removal.
Partial methylation was detected in the CGI of
MAGEA3 and HSPC105 genes that were actively tran-
scribed in untreated cells however no methylation was
detected in the CGI associated with the beta-actin house-
keeping gene in any of the cell lines tested. The MAGEA3
and HSPC105 genes in HCT116 and HT29 cells respec-
tively, were both expressed and with CGI methylation of
~50-60% suggesting only one allele was hypermethylated.
HCT116 and SW48 cells are of particular interest since
the hypermethylation of the promoter regions of
CDKN2A  (NM_000077.3) and MLH1  respectively are
considered to result in the repression of these genes'
expression. In the HCT116 cells, the CDKN2A CGI dis-
played a region of 50% methylation in the vicinity of the
TSS that spanned at least 100 bp (Additional File 6: Figure
S6). Consequently, CDKN2A expression was detected at
all times points in these cells. With the exception of
SW48, MLH1 was expressed in all cells, and no methyla-
tion was detected in MLH1 CGI. After 10 days of drug
free growth, MLH1 was still expressed in SW48 cells, but
Table 2: Genomic methylation of cells treated with 5-aza-dC alone and in combination with TSA.
Time after 5-aza-dC 5-aza-dC & TSA 5-aza-dC alone p-value
day 0 1.52% 1.18% 0.06
day 2 1.55% 1.52% 0.82
day 4 2.29% 2.32% 0.60
day 6 2.29% 2.37% 0.14
day 8 2.31% 2.38% 0.31
day 10 2.41% 2.39% 0.76
Global methylation levels decreased with 5-aza-dC treatment and were gradually restored. T-test p-values indicate there is no synergistic 
effect caused by histone acetylation in the demethylation of genomic DNA.
Table 3: Commonly reactivated genes in 5-aza-dC treated 
colorectal cancer cells
Accession No. Gene Name
NM_203339.1 Clusterin
NM_176791.3 Gametocyte specific factor 1-like
NM_173357.2 Synovial sarcoma, × breakpoint 6 (Pseudogene)
NM_144701.2 Interleukin-23 receptor
NM_080618.2 CCCTC-binding factor (zinc finger protein)-like
NM_032598.3 Spermatogenesis associated 22
NM_012253.2 Transkelotase-like 1
NM_006001.1 Tubulin alpha 3C
Eight genes were commonly reactivated across the five cell lines 
exposed to 5-aza-dC for 72 h.
Table 4: Expression patterns of reactivated genes.
Cell Line Short Term Long Term Other
Fibroblasts 626 453 356
HCT116 511 702 244
HCT116 + TSA 354 943 134
SW480 383 650 246
SW48 525 778 248
HT29
LoVo
551
1116
670
597
257
185
Short term genes were transiently reactivated with 5-aza-dC 
whilst long term genes were still expressed 10 d post treatment. 
Other refers to any pattern other than short or long term re-
expression.Mossman et al. BMC Cancer 2010, 10:366
http://www.biomedcentral.com/1471-2407/10/366
Page 6 of 10
this did not correlate with the methylation status of the
MLH1 CpG island, which was hypermethylated.
While some genes were still highly expressed 10 days
after 5-aza-dC treatment, there were a group of genes
which were temporarily up-regulated or re-expressed but
were expressed at low levels after 10 days of drug free
growth. Genes in this category that were studied include
the  ZFP3  (NM_153018.1) (Figure 3) and RNF113B
(NM_178861.3) genes in the HT29 cell line. De-methyla-
tion was observed at the RNF113B CGI after 5-aza-dC
exposure and this level returned to normal levels 10 days
after removal of the 5-aza-dC. Genes classified as tempo-
rarily reactivated by 5-aza-dC had uniform levels of
hypermethylation, unlike those classified as 'permanently'
reactivated which carried hypomethylated CpG sites.
Discussion and Conclusions
The involvement of epigenetic factors, particularly DNA
methylation on the regulation of gene expression has
been recognised for quite some time, however it is a pro-
cess not totally understood. The events which underlie
genomic hypomethylation and hypermethylation of
tumour suppressor genes in malignant cells and why
these types of genes are targeted remain unresolved.
HPLC analysis of genomic DNA was performed to assess
the level of total methylation content present in several
types of CRC cells. Genome wide hypomethylation was
observed in all the CRC cell lines analysed when com-
pared with the fibroblast cell line, and the lower levels of
global methylation in the LoVo and HT29 cell lines may
contribute to the genomic instability observed in these
cell lines. This finding is consistent with previous reports
that malignant cells have lower levels of genomic DNA
methylation when compared with healthy tissues [23,24].
The de-methylation observed on a global level did not
correlate with that found at specific CGIs, and conse-
quently, expression was observed from genes associated
with a hypermethylated promoter. The discrepancy
between global and specific gene methylation levels can
be explained by the reduced methylation level of Alu ele-
ments and LINE methylation. Yang and colleagues [25]
demonstrated Alu elements and LINE methylation is
reduced by 16% and 60% respectively in colorectal cancer
cell lines treated for 72 h with 5-aza-dC. Repetitive
regions are likely to fall within compacted heterochroma-
tin where methyltransferase access to the DNA is limited
and as a result these sequences become more readily
hypomethylated. Furthermore, methylation reductions in
a combination of transposable elements [5], satellite
repeats [26] and other methylated GC rich areas of the
genome which do not form bona fide CpG islands [27]
may also contribute to this difference.
Global methylation levels and response to 5-aza-dC and 
TSA
In all cell lines studied significant genome-wide de-meth-
ylation was observed, and a greater than 50% reduction
was observed in SW48, SW480 and HCT116 cells, indi-
cating significant DNA de-methylation. Amongst the
cancer cells, higher pre-treatment levels of global methy-
lation appeared to correlate with a larger decrease in
Figure 2 Selection of genes for bisulphite sequencing analysis. 
Shown in the heatmap are the genes reactivated in the SW480 cell line. 
Filters were applied to select silenced genes that were reactivated 
upon 5-aza-dC treatment. Genes demonstrating differential expres-
sion between cell lines were chosen for further analysis.
Figure 3 MAGEA3 and ZFP3 CGI methylation and expression with 
5-aza-dC treatment. Figure 3A illustrates hypomethylated cytosines 
at the TSS in otherwise hypermethylated CpG island and the corre-
sponding expression (B). Figure C and D shows CGI hyper-methylation 
and expression of the temporarily reactivated ZFP3 gene in HT29 cells.Mossman et al. BMC Cancer 2010, 10:366
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global methylation levels. Even with exposure to a high
concentration of 5-aza-dC, global methylation levels fol-
lowing treatment averaged ~1.2% in the colorectal cancer
cell lines. This may be interpreted to suggest that if total
methylation levels fall below this point, cell death may be
induced either through de-methylation, or toxicity from
excessive DNMT binding to DNA. Further analysis of
DNA with genome wide methylation arrays might reveal
regions that are common to all cell lines which are resis-
tant to DNA de-methylation induced by 5-aza-dC. This
possibility was not examined in the current study.
By the tenth day of drug free growth, the global methy-
lation of all cell lines had increased and was nearing pre-
treatment levels. The rate of re-methylation was steady in
the SW480, LoVo, HT29 and fibroblast cell lines, whilst
periods of rapid re-methylation were observed in
HCT116 and SW48 cell lines (Figure 1). Despite genomic
methylation increasing, the rate was reduced dramati-
cally after this point which may suggest levels have, or
could, plateau below the original level. This scenario
could be indicative of an altered pattern of gene expres-
sion following 5-aza-dC treatment. The HCT116 and
SW48 cell lines are known to harbour epigenetic changes,
and were among the most affected by 5-aza-dC which
may suggest regulation of DNA methylation in these cell
lines is different from the others studied.
Continual exposure of the HCT116 cells to Trichostatin
A was performed in combination with regular 5-aza-dC
treatment to investigate whether altering histone acetyla-
tion and chromatin conformation could affect the DNA
methylation process and subsequent gene expression pat-
terns. TSA is an inhibitor of Histone Deacetylase and
leads to histone hyper-acetylation. Histone acetylation is
associated with regions of active chromatin [28] and has
been shown to assist the binding of a the TFIIIA tran-
scription factor to chromatin templates [29]. With this
knowledge, an investigation into whether global de-meth-
ylation could be enhanced and if re-methylation could be
restricted by histone hyper-acetylation was undertaken.
Our results show that at a genome wide level, TSA did
not enhance the de-methylation process in HCT116 cells,
and continual exposure to TSA for ten days did not sig-
nificantly alter the re-methylation process (Table 2) in the
HCT116 cell line. The p-value of 0.06 indicates the largest
difference is at the d0 time point, however at this time the
TSA treated cell line had a greater level of global methyla-
tion, and therefore did not enhance de-methylation.
Based on these observations, DNA methylation is not
hindered by histone acetylation. This notion does not
conflict with previous findings that 5-aza-dC and TSA
have a synergistic effect on gene expression [17,30] rather
it indicates methyltransferase enzymes are not deterred
from hyper-acetylated DNA.
Expression arrays were conducted with the aim of iden-
tifying reactivated genes that were differentially
expressed between the cell lines and could be subjected
to bisulfite sequencing analysis. In addition, the influence
of TSA on expression patterns could be observed. Com-
bined treatment of TSA with 5-aza-dC did not cause an
increase in the number of reactivated genes which is in
accordance with its minor influence on genomic methyla-
tion levels. Again, this does not conflict with previous
reports of a synergistic effect of the two drugs, but indi-
cates DNA methylation plays a greater role than histone
acetylation in reactivating silenced genes on a genome
wide level [20]. The synergistic effect of TSA was
observed with prolonged expression of 165 genes deemed
temporarily reactivated with 5-aza-dC alone, implicating
TSA treatment as a valuable tool for maintaining expres-
sion of genes reactivated with 5-aza-dC.
The combined use of 5-aza-dC and TSA may be advan-
tageous in overcoming poor outcomes in tumour types
that do not respond to 5-aza-dC alone. A 'maintenance'
administration of TSA following a 5-aza-dC treatment
cycle may assist with prolonged gene expression without
the cytotoxic effects of 5-aza-dC. Furthermore, identifi-
cation of the pre-existing methylation patterns at genes
targeted for reactivation could determine whether that
gene will respond to treatment and whether a particular
patient is suitable for this type of therapy.
Bisulphite sequencing of CpG islands
Bisulphite conversion of DNA followed by PCR and
direct sequencing across a CGI permits quantification of
the methylation at individual CpG sites and allows for the
establishment of a methylation profile of CpG islands.
The genes studied displayed varying levels of responsive-
ness to 5-aza-dC treatment, as observed by a decreased
CGI methylation, however the decrease was not consis-
tent with that observed on a genome wide level. The larg-
est decrease in gene specific methylation was in the
RNF113B gene. After treatment, CGI methylation levels
dropped by over 20% in the HT29 cell line with an associ-
ated increase in gene expression. By the tenth day of
drug-free growth the CGI methylation returned to pre-
treatment levels, which correlated with the return of nor-
mal levels of gene expression.
Sequencing of CGIs allowed the detection of several
instances where a small cluster of cytosines were hypom-
ethylated amongst an otherwise hypermethylated CpG
island in a non-expressed gene. These hypomethylated
cytosines appear at a CpG site adjacent to the TSS of a
gene, as seen in the MAGEA3 CGI in SW480 cells. Upon
culturing the cells for a further four and ten days in drug
free media, these cells were found to still be expressing
the previously silenced MAGEA3 gene, suggesting theMossman et al. BMC Cancer 2010, 10:366
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transcriptional status of this gene had been permanently
reversed. In comparison, the HCT116 cell line expressed
these two genes constitutively. The only common methy-
lation pattern amongst the two cell lines was <50% meth-
ylation at the CpG sites 1 bp upstream and 10 bp
downstream of the TSS in the MAGEA3 gene. This kind
of reactivation was also observed in CDO1, and HSPC105
genes in SW480 cells which also carried hypomethylated
CpG sites.
To investigate the possibility that the enduring reactiva-
tion of genes was due to continued cytotoxicity or apop-
tosis, we monitored these levels over the corresponding
time period. Both cytotoxicity and apoptosis levels were
elevated by 5-aza-dC, but decreased when the drug was
removed. This indicates gene expression variation is a
result of changes in genomic methylation rather than
activation of apoptotic pathways. The fraction of necrotic
cells remained higher than in untreated cells which are
likely to represent reactivated genes that orchestrate cell
death or cells that died in the time prior to the measure-
ment of apoptosis.
Treatment of cells with 5-aza-dC caused the reactiva-
tion of numerous genes, although de-methylation within
the CGI of specific genes did not correlate with genomic
levels (as discussed earlier) or transcription levels. Conse-
quently we observed that 5-aza-dC induced expression
can be driven from a largely methylated promoter with
localised demethylation at the TSS. One such example is
the CDO1 gene in SW480 cells (Additional File 7: Figure
S7), where ~10% de-methylation (ie 10% of all alleles) at
three CpG sites caused a greater than 1000-fold up-regu-
lation of CDO1 mRNA.
We envisage the significant increase in expression of
CDO1 is inflated due to non-existent expression in
untreated cells, and that modest expression is permitted
due to hypomethylation in a small proportion of cells at
the TSS. As methylation of surrounding CpG sites was
largely unaltered, demethylation of three CpG sites in a
50 bp region surrounding the TSS is permissive of tran-
scription, and does not require hypomethylation of the
entire allele. A similar finding has been previously
reported in CDKN2A in cervical carcinogenesis [31] and
also in the CDH1 gene in [32]. The minor demethylation
of  CDH1  in conjunction with large increase of gene
expression may suggest that DNA methylation does not
repress transcription, and gene up-regulation could be
due to either a secondary effect or the involvement of
other factors which are also modified by 5-aza-dC treat-
ment.
Clusters of CpG sites were identified in some genes that
showed a region of hypomethylation, such as MAGEA3
in HT29 cells (Additional File 4: Figure S4) and ZFP3 in
the SW480 cells (Additional File 8: Figure S8). Expression
of these genes was detected before 5-aza-dC treatment,
demonstrating the importance of methylation in the CpG
sites around the TSS, and how a region of hypomethyla-
tion is permissive of transcription. Methylation of ~50%
w a s  d e t e c t e d  a t  s o m e  C G I s  i n c l u d i n g  CDKN2A  in
HCT116 cells. These genes are likely to show mono-
allelic methylation which has been reported previously
[33,34], where all expression is from one non-methylated
allele.
The  MLH1  gene is silenced by methylation on both
alleles in SW48 cells [35]. Following 5-aza-dC treatment,
de-methylation was induced and the gene was re-
expressed and by the tenth day of drug free growth, the
gene was still expressed despite methylation returning to
pre-treatment levels. The expression level of MLH1  at
day 10 may be due to lower methylation at a CpG site 32
bp downstream from the TSS, which is similar to the long
term reactivation in the CDO1, MAGEA3 and HSPC105
genes in SW480 cells. The analysis undertaken suggests
that genes thought to be under control of epigenetic
modifications such as CDKN2A  and  MLH1  were not
shown to have significantly altered patterns of CpG
methylation following 5-aza-dC treatment, although an
increase in expression was observed.
In non-expressed genes, the identification of regions of
hypomethylated cytosine in a generally hypermethylated
CpG island raises the question of how these cytosines are
maintained in a hypomethylated state. As the region of
hypomethylated cytosines in these genes is less than 146
bp - the length of DNA associated with a nucleosome, it
w o u l d  s u g g e s t  i n  t h i s  s c e n a r i o  a t  l e a s t ,  a n  a b s e n t
nucleosome is not a factor in assisting transcription as
previously described [36]. It would appear 5-aza-dC can
induce an irregular nucleosomal conformation that per-
mits expression from methylated genes. It is also possible
that 5-aza-dC reduces repressive histone tail marks or
initiates the gain of active marks in the area surrounding
the hypomethylated cytosine following 5-aza-dC expo-
sure. The methylation of Histone H3 Lysine 9 is a modifi-
cation associated with inactive chromatin and has been
shown to be rapidly lost with 5-aza-dC treatment [37]. It
is possible that a loss of H3K9 methylation may have been
induced by 5-aza-dC in the current study, which may
allow binding of transcriptional proteins, which in turn
enhance transcriptional reactivation.
Hypomethylated CpG sites which exert control on gene
expression may have implications for methods such as
methylation-specific PCR and array technologies which
rely on the methylation status of a small number of CpG
sites in order to determine a given genes methylation sta-
tus. The observation that a single or small group of CpG
sites could affect expression may have greater implica-
tions should a polymorphism exist at the site. A polymor-
phism at the CG dinucleotide will deny methyl-group
attachment which would be advantageous to individualsMossman et al. BMC Cancer 2010, 10:366
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with that change by conferring a protective effect against
epigenetic inactivation, particularly in genes such as
MLH1.
Our results show that 5-aza-dC induces gene expres-
sion, but is not necessarily dependant on DNA de-methy-
lation. The pre-existing level of methylation surrounding
the transcriptional start site of a gene appears important
in long term reactivation. This was demonstrated as the
transcriptional status of silenced genes could be reversed
with 5-aza-dC and for up to ten days after its removal in
genes with hypomethylated cytosines despite minimal
CpG de-methylation. In CGIs which exhibited a uniform
level of hypermethylation, transcription could be induced
for a short term only. The acetylation of histones was not
found to alter the de-methylation or re-methylation pro-
cess and was therefore not expected to cause a change in
the gene expression profile. Although constitutively
expressed genes demonstrate hypomethylation, 5-aza-dC
treatment was found to force expression from genes with
hypermethylated CGIs, suggesting that 5-aza-dC is capa-
ble of influencing other factors involved with gene
expression, such as proteins with a methyl-binding
domain or histone modifications.
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